Overview of Cardium

Quick Facts

Property	Description
Active Ingredients	Diltiazem HCl, Levomefolic Acid, Methylcobalamin, Pyridoxal 5-phosphate
Form	Oral Tablet or Capsule
Pharmacological Class	Calcium-Channel Blocker (Non-dihydropyridine) and B-Vitamin Complex
General Purpose	Cardiovascular stability and metabolic support
Origin	Synthetic and Derived

What Type of Medicine is Cardium?

Cardium is a specialized prescription combination pharmacological product combining an established cardiovascular drug with a targeted blend of essential vitamins. It is classified as a dual-class medicine, delivered in a solid oral dosage form. The primary drug component, Diltiazem Hydrochloride, positions it within the non-dihydropyridine Calcium-Channel Blocker (CCB) pharmacological class. This class is utilized for its ability to dilate blood vessels and regulate heart rhythms. This formulation is specifically characterized by integrating two therapeutic strategies, setting it apart from standard monotherapies by combining a synthetic cardiovascular agent with three derived and biologically active cofactors.

Composition: Active Ingredients in the Cardium Formulation

The active ingredients in Cardium are Diltiazem Hydrochloride and a complex of three activated B-vitamins: Levomefolic Acid, Methylcobalamin, and Pyridoxal 5-phosphate. Diltiazem is a widely studied synthetic compound acting on heart and vascular muscle cells, while the B-vitamins are included in their metabolically ready, coenzyme forms, ensuring high bioavailability for cellular processes. Levomefolic Acid is the primary biologically active form of folate, utilized by the body without requiring metabolic conversion. This composition differentiates Cardium from generic Diltiazem products which lack the B-vitamin complex.

General Purpose: What is Cardium Designed to Achieve?

Cardium is fundamentally designed to support and stabilize cardiovascular function through its primary drug component. A typical use scenario involves stabilizing the heart's electrical activity or managing elevated blood pressure. The key function of the Diltiazem component is to promote vascular relaxation and help manage heart rhythm. The complementary activated B-vitamins aim to provide necessary metabolic support for the health of the nervous system and the circulatory system lining, thereby contributing to the overall maintenance of blood vessel integrity and cardiac efficiency.

What side effects are possible with Cardium?

Possible Side Effects and Safety Information

The safety profile of Cardium is predominantly defined by the established regulatory characteristics of its primary component, Diltiazem Hydrochloride, a calcium-channel blocker. Adverse reactions are formally classified by frequency and grouped into System-Organ Classes (SOC) as documented in official government labeling.

Adverse Reaction Frequencies

The incidence of potential side effects ranges from Very Common to Rare, based on regulatory classifications:

Very Common: Peripheral oedema (swelling, particularly of the lower limbs).
Common (1% to 10%): Headache, dizziness, bradycardia (slowed heart rate), constipation, nausea, and flushing. Cardiac conduction effects, such as first-degree Atrioventricular (AV) block, are also classified as common.
Uncommon/Rare: Uncommon effects include nervousness, insomnia, vomiting, and elevated liver enzymes. Rare effects include dry mouth and urticaria.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents list several reactions as clinically serious. These include the potential development of Second- or Third-Degree Atrioventricular Block, worsening of Congestive Heart Failure in pre-existing conditions, Acute Hepatic Injury, and severe dermatological reactions like Stevens-Johnson syndrome (SJS).

Regulatory labeling also notes that the incidence and severity of certain effects, such as first-degree AV block, are often documented to increase as the dose increases. Furthermore, specific safety cautions are advised for use in older adults (who may experience vasodilatory effects more frequently) and individuals with impaired renal or hepatic function.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

An overdose of Cardium, primarily due to the Diltiazem component, is associated with a specific profile of cardiovascular manifestations documented in official regulatory labeling. These documented clinical signs include severe Hypotension (low blood pressure) and profound disturbances in heart rate, such as Bradycardia (abnormally slow heart rate), alongside conduction issues like First-degree Atrioventricular Block. Systemic effects, including dizziness, fatigue, and somnolence, may also be documented presentations.

Overdose may escalate to serious, life-threatening outcomes, including Cardiogenic Shock and the documented risk of Cardiac Arrest or Asystole (cessation of heart activity). Individuals must seek immediate medical attention and contact emergency services immediately if an overdose is suspected, as immediate hospitalization is required for managing these severe symptoms.

Management and Monitoring

Official labeling describes management involving Symptomatic and Supportive Treatment. Procedures documented for healthcare providers may include gastric lavage or the administration of Activated Charcoal. Agents such as Intravenous Calcium Gluconate and Vasopressors are specified for managing profound cardiovascular depression, although it is noted that no specific antidote is known for this class of medicine. Regulatory authorities mandate Continuous Electrocardiographic (ECG) monitoring and extended observation due to the risk of delayed effects. An increased susceptibility to severe symptoms is documented for patients who are elderly or have pre-existing hepatic impairment.

Therapeutic Uses of Cardium

Cardium is applied across domains where additional symptomatic support is needed in the management of chronic heart conditions. This medication is typically utilized to help with high blood pressure, may assist with chest pain, and may also play a role in managing certain types of abnormal heart rhythms. This therapeutic scope is relevant across domains where additional symptomatic support is needed.

The medication is commonly used to help manage symptomatic patterns related to Hypertension, Chronic Stable Angina, and specific Atrial Arrhythmias (like Atrial Fibrillation and PSVT). This approach provides support that helps ease the overall symptom load, particularly when symptoms, like an excessively fast heartbeat, create noticeable interference with daily function.

“Cardium is applied in clinical settings marked by the need for continuous stabilization, supports patients during episodes of heightened discomfort and assists with maintaining functional stability.”

The B-vitamin component further contributes to improved comfort during symptomatic periods by managing metabolic markers, such as Elevated Homocysteine Levels, which is considered relevant in contexts involving heightened systemic burden.

Quick Fact	Relief for Symptom
Commonly Applied For	High Blood Pressure and Angina
Symptom Focus	Rapid Heart Rate and Ischemic Chest Discomfort
Patient Benefit	Assists with maintaining functional stability

Regulatory References

NIH MedlinePlus overview of Diltiazem

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cardium — Official Regulatory Information

This section defines the official eligibility and non-eligibility for using Cardium, based strictly on government regulatory documents, focusing on established contraindications and population restrictions.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (18 years of age and older) for the stated indications.
Populations for whom use is contraindicated	Patients with Sick Sinus Syndrome or Second- or Third-Degree AV Block (unless a functioning pacemaker is present).
	Patients with Severe Hypotension (low blood pressure) or those with Acute Myocardial Infarction combined with Pulmonary Congestion.
	Patients with known Hypersensitivity to Diltiazem or any formulation component.
Age-related eligibility rules	Pediatric Use is Not Established; safety and effectiveness have not been demonstrated in patients under 18 years of age.
	Geriatric Use requires caution and monitoring due to potential age-related decline in organ function.
Condition-specific eligibility rules	Use requires Caution in patients with Hepatic Impairment (liver dysfunction) or Renal Impairment (kidney dysfunction).
Pregnancy and lactation eligibility status	Use is Not Recommended during Pregnancy or Lactation due to potential risk.

Resulting Eligibility Structure

Official eligibility statements strictly prohibit Cardium use in individuals with serious pre-existing cardiac conduction defects or severe hemodynamic instability, classifying these as absolute contraindications. Use is strictly limited to the adult population, as safety and efficacy have not been established in pediatric groups. Furthermore, the profile dictates that use is not recommended during pregnancy or breastfeeding and requires specific caution when the patient has impaired liver or kidney function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cardium's documented interaction profile is defined by its two main components: Diltiazem and the B-vitamin complex. The most severe constraints involve the Diltiazem component, where co-administration with intravenous beta-blockers and Ivabradine is formally contraindicated due to the risk of significant additive effects on cardiac function.

Diltiazem acts as an inhibitor of hepatic microsomal enzymes (e.g., CYP3A4). This pharmacokinetic interaction can lead to an increase in the plasma concentration and systemic exposure of many co-administered substances, including Cyclosporine and certain statins. Furthermore, additive pharmacodynamic effects are noted when Diltiazem is combined with oral beta-blockers, increasing the risk of bradycardia and AV block.

The activated B-vitamin components interact bidirectionally with certain medicines. For example, Levomefolic Acid can decrease the serum concentration of certain anticonvulsants (e.g., Phenytoin), while other drugs like Colchicine or Sulfasalazine may reduce the absorption or concentration of the B-vitamins. Regarding substances, the regulatory label notes that both Grapefruit and Alcohol can increase Diltiazem exposure. Concurrent use with Alcohol is not recommended due to the potential for severe, additive drowsiness linked to the Pyridoxal 5-phosphate component. A specific condition for administration is that if the capsule contents are mixed with applesauce, they must be swallowed immediately.

Mechanism of Action

Cardium is a calcium ion cellular influx inhibitor, also classified as a slow channel blocker. Its primary biological target is the voltage-dependent L-type calcium channel found in the sarcolemma of myocardial tissue and vascular smooth muscle. By binding to these channels, Cardium allosterically and/or directly inhibits the transmembrane influx of extracellular calcium ions into the cell during membrane depolarization. This reduction in intracellular calcium concentration leads to two key downstream cascades: inhibition of actin-myosin coupling in vascular smooth muscle, resulting in vasodilation and a subsequent decrease in peripheral vascular resistance; and a reduction in calcium delivery to myocardial contractile proteins, which decreases cardiac chronotropy (heart rate) and dromotropy (AV nodal conduction velocity). The resulting system-level physiological consequence is a simultaneous reduction in systemic blood pressure and modulation of myocardial oxygen demand.

Dosage and Administration Information

General Principles of Use

Cardium is an oral extended-release prescription medication intended for long-term chronic administration. The dosing regimen is designed to be once daily to ensure the continuous, 24-hour controlled release of the diltiazem component. To maintain stable drug levels, the dose should be taken at approximately the same time each day.

Official Dosing and Administration

Category	Labeled Instruction Principle
Route & Frequency	Oral administration, once daily (24-hour extended release).
Standard Initial Dose	Typically initiated at 180 mg to 240 mg once daily.
Dose Titration	Dosage adjustments are made gradually, generally at intervals of 7 to 14 days, allowing the full response to be assessed before a subsequent change. The maximum labeled dose can be up to 540 mg once daily for some indications.
Physical Integrity	The extended-release tablet or capsule must be swallowed whole to preserve the controlled-release mechanism; it must not be cut, crushed, or chewed.
Administration Context	The drug may be taken with or without food. For specific capsule formulations, the contents may be opened and sprinkled onto a spoonful of soft food like applesauce, but this mixture must be swallowed immediately without chewing.
Population Adjustment	A lower starting dose and cautious titration are recommended by prescribing information for older adults and patients with hepatic (liver) or renal (kidney) impairment.

Missed Dose Guidance

If a dose is missed, it should be taken as soon as it is remembered on the same day. If it is almost time for the next scheduled dose, the missed dose is skipped, and the regular schedule is resumed. Two doses should not be taken together to compensate for the missed one. This procedure ensures the proper continuous release profile is not compromised.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cardium

The research evidence for Cardium is drawn from studies focused on its two main components: the primary cardiovascular medicine (Diltiazem) and the integrated B-vitamin complex (Levomefolic Acid, Methylcobalamin, and Pyridoxal 5-phosphate). These studies primarily examine and research examined physiological processes and symptom patterns related to cardiovascular and metabolic functions. Research highlights what is known and what remains uncertain about the evidence.

Research on Stabilizing Heart Rhythm and Rate (Atrial Arrhythmias)

The evidence supporting the evaluation of the cardiovascular component in conditions characterized by temporary physiological imbalance comes mainly from short-term, controlled clinical trials. Research examined outcomes related to episodic or acute changes in heart activity, monitoring how heart rate evolved in observed populations. These acute trials reported measurements of heart rate over defined time intervals, describing patterns related to heart activity stabilization shortly after administration. Research describes that the component was studied for its effect on heart rhythm patterns. However, certainty remains low regarding the long-term effects of the oral component on heart rhythm patterns after the acute episode has resolved.

Evidence for Managing High Blood Pressure (Essential Hypertension)

The cardiovascular component's evaluation in the context of high blood pressure management was evaluated in numerous randomized controlled trials (RCTs). Research examined outcomes related to physiological strain or stress, specifically monitoring changes in systolic and diastolic blood pressure levels. The data suggest patterns related to blood pressure change in the studied populations of adults with mild-to-moderate high blood pressure. These foundational studies primarily focused on the Diltiazem component as a standalone therapy. Consequently, there is limited information for long-term outcomes (e.g., in the context of stroke or heart attack risk), and the results apply only to the specific hypertensive populations studied.

Research on Metabolic Support and the Homocysteine Biomarker

Research on the B-vitamin component focuses on outcomes related to systemic or functional imbalance, specifically the concentration of the Homocysteine biomarker. Studies describe consistent patterns related to a documented change (reduction) in blood Homocysteine levels. Research describes a pattern of consistency across many populations studied. However, a critical area of uncertainty remains: when researchers examined the results of the same long-term trials for the B-vitamin component's impact on hard clinical endpoints (such as stroke, heart attack, or cardiovascular mortality), the findings were mixed or suggested no corresponding change in these major events.

Key Studies & References ACC/AHA/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Frequently Asked Questions (FAQ)

Common questions about Cardium (FAQ)

Q: How long after starting Cardium might I notice a change?

A: Cardium is designed for long-term use. Official instructions show that when dosage adjustments are considered, they are often done gradually, typically at intervals of 7 to 14 days. This extended period is used to assess the intended full physiological response to the medication before a change is made.

Q: Can I drink alcohol in moderation while taking Cardium?

A: Official regulatory documents advise against the concurrent use of alcohol with Cardium. Alcohol has the potential to increase the systemic concentration of the Diltiazem component. Furthermore, when combined with the Pyridoxal 5-phosphate component, alcohol may lead to an increased risk of severe drowsiness, so concurrent use of alcohol is discouraged in official documents.

Q: Is Cardium ever used in combination with other heart medications?

A: The official product information addresses this by listing specific contraindications, which are combinations that must be avoided, such as intravenous beta-blockers and Ivabradine. Other combinations, such as with oral beta-blockers, are noted to require caution due to the potential for additive effects on heart function.

Q: Are there any specific warnings for women of childbearing age regarding Cardium?

A: Regulatory labeling states that use of Cardium is not recommended during pregnancy or lactation due to potential risks. Information on the effects on human male or female fertility is generally limited in official labeling, which is consistent with the regulatory documents.

Q: How quickly would an interaction with another drug occur after taking Cardium?

A: Regulatory documents describe that Cardium can inhibit certain liver enzymes (like CYP3A4) that process other medicines, which can lead to higher systemic exposure of those co-administered drugs. The time it takes for a clinical interaction to manifest can vary significantly and depends on the specific properties of the drug being interacted with.

Q: Can Cardium be used for other issues besides the main conditions listed?

A: Official regulatory documents describe that Cardium is only approved and intended for the specific cardiovascular conditions for which its use is explicitly labeled. Regulatory agencies do not provide information on the use of the drug for unapproved indications.

Q: What is the general duration of treatment with Cardium?

A: Cardium is explicitly described in official documents as being intended for long-term chronic administration to manage its labeled conditions. The drug is not intended for short-term or acute use.

Q: Is Cardium a type of blood thinner?

A: No, Cardium is not classified as a blood thinner. It belongs to the pharmacological class known as a Calcium-Channel Blocker (CCB). This class of medicine works by influencing the movement of calcium ions in heart and vascular muscle cells, a mechanism distinct from anti-platelet agents or anticoagulants.

Q: Does Cardium cause weight gain or weight loss?

A: Official regulatory documents contain a comprehensive list of known adverse reactions for Cardium. Weight gain or weight loss are not listed among the documented and categorized Common, Very Common, or Uncommon adverse reactions in this official product information.

Q: Does Cardium cause sleep issues or insomnia?

A: Official regulatory labeling lists insomnia (difficulty sleeping) as an Uncommon potential adverse reaction. This means it has been reported in a small percentage of patients during controlled studies.

Q: Does Cardium affect fertility?

A: Official regulatory information indicates that while animal studies may have suggested some effects on fertility, information on the effects on human male or female fertility is generally limited in official labeling.

Q: Does Cardium help prevent future heart events?

A: Research on the Diltiazem component for blood pressure primarily focused on short-term changes in blood pressure levels. Official research documentation notes that there is limited information regarding the drug's long-term outcomes, such as its impact on the risk of stroke or heart attack.

Q: Can Cardium be taken by people with diabetes?

A: Diabetes is not listed as a formal contraindication in official regulatory documents. While diabetes is not listed as a formal contraindication, official information notes that conditions affecting organ function, such as hepatic or renal impairment, require caution and monitoring.

Q: Are there different strengths of Cardium, and why?

A: Regulatory documents list different available dosage strengths for Cardium. These different strengths are described as being necessary to allow for the gradual adjustment of the dose, known as titration, which is part of the overall strategy for managing the condition.

Q: What should I do if a side effect of Cardium seems unusual or severe?

A: Official patient information describes that for severe adverse reactions, such as those listed as clinically serious (e.g., Second- or Third-Degree AV Block, Acute Hepatic Injury, Stevens-Johnson syndrome), urgent medical evaluation is typically warranted.

Q: How does Cardium affect blood pressure?

A: Cardium's mechanism of action involves slowing the movement of calcium ions into vascular smooth muscle cells. This action promotes blood vessel relaxation, which reduces resistance in the body's circulation, leading to a reduction in systemic blood pressure.

Q: Are there any specific laboratory tests required while taking Cardium?

A: Official documents list elevated liver enzymes as an uncommon adverse effect, and caution is advised for patients with existing hepatic (liver) impairment. This information highlights areas where monitoring may be necessary.

Q: Is Cardium a common cause of muscle pain?

A: Muscle pain is not listed among the documented and categorized Common, Very Common, or Uncommon adverse reactions in the official regulatory documents for Cardium's components.

Q: Do I need a special diet while on Cardium?

A: Official regulatory documents do not specify a comprehensive special diet. However, they do note that certain substances, specifically Grapefruit and Alcohol, can increase the systemic exposure of the Diltiazem component, and consumption of alcohol is discouraged.

Q: What are the general research themes explored regarding Cardium?

A: The research evidence themes explored in official studies focus on three main areas: the evaluation of the drug component for stabilizing heart rhythm and rate, its role in managing high blood pressure, and the metabolic support function of the B-vitamin component related to the Homocysteine biomarker.

How should Cardium be stored and disposed of?

How to Store and Dispose of Cardium

Cardium (Diltiazem HCl) must be stored according to specific regulatory requirements to maintain its stability.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, 25 C (77 F), with excursions permitted between 15 C and 30 C.
Protection	Protect from light, avoid excessive humidity, and keep from freezing.
Packaging	Dispense in a light-resistant, tight container with a child-resistant closure.

Disposal and Safety

The medicine must be kept out of the reach of children. For disposal, the official method is using a drug take-back program. If a take-back program is unavailable, the expired or unused product must be mixed with an unappealing substance, placed in a sealed bag, and then disposed of in the household trash.

Cardium